Posts Tagged ‘Leqembi’
Systematic review finds more clinical harm than benefits in Alzheimer’s “treatments” lecanemab, aducanumab, and donanemab
Study questions benefit of new Alzheimer’s drug (UGA Today): Last summer, the U.S. Food and Drug Administration fully approved the first drug shown to slow the progress of Alzheimer’s. But new research from the University of Georgia suggests that patients and caregivers may not experience any benefit from the drug in their daily lives. The drug, Leqembi,…
Read MoreOn neuroplasticity, cognition, aging, medication, Alzheimer’s, board games, brain teasers, and more
Welcome to a new edition of SharpBrains e‑newsletter, featuring fascinating research findings on neuroplasticity, cognition, aging, medication, Alzheimer’s, board games, and more, plus some brain teasers to get you in great shape for Halloween. #1. Study: Playing board games like Chess, Mahjong, Go, helps slow cognitive decline as we age (but with clear differences in…
Read MoreFour reasons to question “new generation” monoclonal antibody Alzheimer’s drugs such as aducanumab (Aduhelm), lecanemab (Leqembi), donanemab
New Alzheimer’s Drugs Don’t Deserve the Hype (Being Patient): A prominent childhood memory is of my grandparents living with and then dying from dementia. As is universal with dementia, there was a double blow: watching my grandparents lose their identity and seeing the suffering of those closest to them.
Read MoreTime for a universal “exercise prescription” for kids and adults to boost cognition and mental health?
Welcome to a new edition of SharpBrains e‑newsletter, featuring this time a range of brain research findings, tools and controversies plus some brain teasers to challenge your (and our) working memory. #1. Major evidence review supports an “exercise prescription” for most adults to boost mental health “Higher intensity physical activity was associated with greater improvements”…
Read MoreHopes and Questions raised by Alzheimer’s drug Leqembi (lecanemab)
The FDA has approved Leqembi, the first disease-modifying treatment for early-stage Alzheimer’s and a precursor condition, mild cognitive impairment. Medicare has said it will pay for the therapy. Medical centers across the country are scrambling to finalize policies and procedures for providing the medication to patients, possibly by summer’s end or early autumn. It’s a…
Read MorePrice tag for a questionable Alzheimer’s treatment: $109,000 per patient, per year. Unclear yet: For how many years?
The real costs of the new Alzheimer’s drug, Leqembi — and why taxpayers will foot much of the bill (CBS News): The first drug purporting to slow the advance of Alzheimer’s disease is likely to cost the U.S. health care system billions annually even as it remains out of reach for many of the lower-income seniors…
Read More